Paper41449459
Advanced nanotechnology in enhancing immune checkpoint inhibitors (ICIs) for head and neck cancer therapy.
Jafari Z and 4 others. Cell Commun Signal, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Advanced nanotechnology in enhancing immune checkpoint inhibitors (ICIs) for head and neck cancer therapy. Papers, record 41449459. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41449459
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Advanced nanotechnology in enhancing immune checkpoint inhibitors (ICIs) for head and neck cancer therapy.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Head and Neck Neoplasms | Major topic |
| Immune Checkpoint Inhibitors | Major topic |
| Nanoparticle Drug Delivery System | Major topic |
| Nanomedicine | Major topic |
| Nanoparticles | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | |
| Tumor Microenvironment | |
| Immunity, Mucosal | |
| Tumor Escape | |
| Humans | |
| Animals | |
| Radiation Tolerance | |
| Chemoradiotherapy | |
| Photothermal Therapy | |
| Photochemotherapy |
Source PubMed
References189
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32792853 | Insights into Nanomedicine for Immunotherapeutics in Squamous Cell Carcinoma of the head and neck. | Int J Biol Sci | 2020 | https://conductscience.org/library/papers/32792853 | PubMed |
| 2 | 34305619 | Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34305619 | PubMed |
| 3 | 32467567 | Nanomedicine and cancer immunotherapy. | Acta Pharmacol Sin | 2020 | https://conductscience.org/library/papers/32467567 | PubMed |
| 4 | 35551240 | Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy. | Nat Nanotechnol | 2022 | https://conductscience.org/library/papers/35551240 | PubMed |
| 5 | 39474549 | Therapeutic Host Anticancer Immune Response through Photoimmunotherapy for Head and Neck Cancer May Overcome Resistance to Immune Checkpoint Inhibitors. | Case Rep Oncol | 2024 | https://conductscience.org/library/papers/39474549 | PubMed |
| 6 | 38335850 | Major and durable responses to photon and electron-beam palliative radiotherapies after immune-checkpoint inhibitors in head and neck cancer. | Oral Oncol | 2024 | https://conductscience.org/library/papers/38335850 | PubMed |
| 7 | 9784967 | CD28/B7 costimulation: a review. | Crit Rev Immunol | 1998 | https://conductscience.org/library/papers/9784967 | PubMed |
| 8 | 31741778 | Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. | Oncoimmunology | 2019 | https://conductscience.org/library/papers/31741778 | PubMed |
| 9 | 29560283 | Controlled drug delivery vehicles for cancer treatment and their performance. | Signal Transduct Target Ther | 2018 | https://conductscience.org/library/papers/29560283 | PubMed |
| 10 | 39501968 | Advanced Nanomaterials for Cancer Therapy: Gold, Silver, and Iron Oxide Nanoparticles in Oncological Applications. | Adv Healthc Mater | 2025 | https://conductscience.org/library/papers/39501968 | PubMed |
| 11 | 32942725 | Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology. | Cells | 2020 | https://conductscience.org/library/papers/32942725 | PubMed |
| 12 | 40116158 | A Hybrid Manganese Nanoparticle Simultaneously Eliminates Cancer Stem Cells and Activates STING Pathway to Potentiate Cancer Immunotherapy. | ACS Nano | 2025 | https://conductscience.org/library/papers/40116158 | PubMed |
| 13 | 15176068 | Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. | J Pharm Sci | 2004 | https://conductscience.org/library/papers/15176068 | PubMed |
| 14 | 39335671 | Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy. | Biomedicines | 2024 | https://conductscience.org/library/papers/39335671 | PubMed |
| 15 | 36236192 | Temperature-Responsive Polymer Brush Coatings for Advanced Biomedical Applications. | Polymers (Basel) | 2022 | https://conductscience.org/library/papers/36236192 | PubMed |
| 16 | 24328413 | Photodynamic therapy: oncologic horizons. | Future Oncol | 2014 | https://conductscience.org/library/papers/24328413 | PubMed |
| 17 | 14556006 | Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. | Nat Immunol | 2003 | https://conductscience.org/library/papers/14556006 | PubMed |
| 18 | 31984810 | Stability issues and approaches to stabilised nanoparticles based drug delivery system. | J Drug Target | 2020 | https://conductscience.org/library/papers/31984810 | PubMed |
| 19 | 40190094 | Nanosized Shikonin Disrupts Tumor-Cell Mismatch Repair and Synergizes with Manganese to Sensitize Squamous Carcinoma to Immunotherapy. | ACS Nano | 2025 | https://conductscience.org/library/papers/40190094 | PubMed |
| 20 | 23480658 | Biomedical applications of graphene and graphene oxide. | Acc Chem Res | 2013 | https://conductscience.org/library/papers/23480658 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42654096 | Injectable Hydrogels for Breast Cancer Therapy: From Tumor Microenvironment-Responsive and Actively Targeted Drug Delivery to Immunotherapy and Theranostics. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42654096 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41449459
GET https://conductscience.org/api/papers/v1/41449459/references?page=2